Minocycline is a tetracycline analog used to treat a wide variety of infections in the body. Minocycline was first described in the literacture in 1966.
- Mechanism
- Curator reviewed · 6 references
Tetracyclines enter bacterial cells through OmpF and OmpC porins by coordinating with cations like magnesium. This allows tetracyclines into the periplasm where they dissociate, allowing the lipophilic tetracycline to diffuse into the bacterial cytoplasm. Tetracyclines prevent aminoacyl-tRNA from binding to the 30S ribosome, inhibiting protein synthesis.
- Primary indication
- Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris.Curator reviewed · 25 structured indications
- Formula / weight
- C23H27N3O7 · 457.4764 g/mol (avg)
- First approval
- Canada, 1998 · United States, 1990
- Also known as
- Minocyclin · Minomycin
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
DYKFCLLONBREIL-KVUCHLLUSA-NSMILES[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2Transporters
What you can answer from here — as of September 23, 2026
12Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
4TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Minocycline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account